KCNJ10 and myeloid sarcoma: Compared with studies in healthy controls, three studies in MS patients showed an association of positivity of anti-KIR4.1[10,11,14] and seven studies, including our own, showed no significant differences[12,13,16,20,21,27–29] (Fig 4).